Hidrogel chitosan chứa peptide LL-37 thúc đẩy lành vết thương tổn thương mô sâu trong mô hình chuột
Tóm tắt
Peptide LL-37 là một thành viên của gia đình cathelicidin ở người, và đã được chứng minh là thúc đẩy sự chữa lành của loét do áp lực. Tuy nhiên, sự ổn định thấp của peptide này trong môi trường vết thương hạn chế khả năng sử dụng lâm sàng của nó. Hidrogel chitosan (CS) thường được sử dụng làm vật liệu nền cho chất liệu băng vết thương.
Hidrogel CS (2,5% w/v) được bao encapsulated với LL-37. Độc tính tế bào của sản phẩm được kiểm tra trong các fibroblast NIH3T3 nuôi cấy. Ảnh hưởng đến phản ứng miễn dịch được kiểm tra bằng cách đo lường sự giải phóng yếu tố hoại tử khối u-α (TNF-α) từ các đại thực bào RAW 264.7 khi tiếp xúc với lipopolysaccharide. Hoạt động kháng khuẩn được đánh giá bằng cách sử dụng
Hidrogel LL-37/CS không ảnh hưởng đến khả năng sống của tế bào NIH3T3. Ở nồng độ 1–5 μg/ml, LL-37/CS ức chế sự giải phóng TNF-α từ đại thực bào. Tại 5 μg/ml, LL-37/CS ức chế sự phát triển của
Từ khóa
Tài liệu tham khảo
Artico M, Dante A, D'Angelo D, Lamarca L, Mastroianni C, Petitti T, et al. Prevalence, incidence and associated factors of pressure ulcers in home palliative care patients: a retrospective chart review. Palliat Med. 2018;32(1):299–307.
Demarré L, van Lancker A, van Hecke A, Verhaeghe S, Grypdonck M, Lemey J, et al. The cost of prevention and treatment of pressure ulcers: a systematic review. Int J Nurs Stud. 2015;52(11):1754–74.
Coyer F, Miles S, Gosley S, Fulbrook P, Sketcher-Baker K, Cook JL, et al. Pressure injury prevalence in intensive care versus non-intensive care patients: a state-wide comparison. Aust Crit Care. 2017;30(5):244–50.
Zhao R, Liang H, Clarke E, Jackson C, Xue M. Inflammation in chronic wounds. Int J Mol Sci. 2016;17(12):2085.
Atkinson RA, Cullum NA. Interventions for pressure ulcers: a summary of evidence for prevention and treatment. Spinal Cord. 2018;56(3):186–98.
Espejo E, Andrés M, Borrallo RM, Padilla E, Garcia-Restoy E, Bella F. Bacteremia associated with pressure ulcers: a prospective cohort study. Eur J Clin Microbiol Infect Dis. 2018;37(5):969–75.
Lowry D, Saeed M, Narendran P, Tiwari A. The difference between the healing and the nonhealing diabetic foot ulcer: a review of the role of the microcirculation. J Diabetes Sci Technol. 2017;11(5):914–23.
Xhindoli D, Pacor S, Benincasa M, Scocchi M, Gennaro R, Tossi A. The human cathelicidin LL-37--a pore-forming antibacterial peptide and host-cell modulator. Biochim Biophys Acta. 2016;1858(3):546–66.
Fumakia M, Ho EA. Nanoparticles encapsulated with LL37 and serpin A1 promotes wound healing and synergistically enhances antibacterial activity. Mol Pharm. 2016;13(7):2318–31.
Agier J, Brzezińska-Błaszczyk E, Żelechowska P, Wiktorska M, Pietrzak J, Różalska S. Cathelicidin LL-37 affects surface and intracellular toll-like receptor expression in tissue mast cells. J Immunol Res. 2018;2018:7357162.
Adase CA, Borkowski AW, Zhang LJ, Williams MR, Sato E, Sanford JA, et al. Non-coding double-stranded RNA and antimicrobial peptide LL-37 induce growth factor expression from keratinocytes and endothelial cells. J Biol Chem. 2016;291(22):11635–46.
Hou S, Sun X, Dong X, Lin H, Tang L, Xue M, et al. Chlamydial plasmid-encoded virulence factor Pgp3 interacts with human cathelicidin peptide LL-37 to modulate immune response. Microbes Infect. 2019;21(1):50–5.
Steinstraesser L, Lam MC, Jacobsen F, Porporato PE, Chereddy KK, Becerikli M, et al. Skin electroporation of a plasmid encoding hCAP-18/LL-37 host defense peptide promotes wound healing. Mol Ther. 2014;22(4):734–42.
Grönberg A, Mahlapuu M, Ståhle M, Whately-Smith C, Rollman O. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen. 2014;22(5):613–21.
Garcia-Orue I, Gainza G, Girbau C, Alonso R, Aguirre JJ, Pedraz JL, et al. LL37 loaded nanostructured lipid carriers (NLC): a new strategy for the topical treatment of chronic wounds. Eur J Pharm Biopharm. 2016;108:310–6.
Boateng J, Catanzano O. Advanced therapeutic dressings for effective wound healing--a review. J Pharm Sci. 2015;104(11):3653–80.
Desfrançois C, Auzély R, Texier I. Lipid nanoparticles and their hydrogel composites for drug delivery: a review. Pharmaceuticals (Basel). 2018;11(4):E118.
Das S, Baker AB. Biomaterials and nanotherapeutics for enhancing skin wound healing. Front Bioeng Biotechnol. 2016;4:82.
Naseri-Nosar M, Ziora ZM. Wound dressings from naturally-occurring polymers: a review on homopolysaccharide-based composites. Carbohydr Polym. 2018;189:379–98.
Gao J, Zheng W, Zhang J, Guan D, Yang Z, Kong D, et al. Enzyme-controllable delivery of nitric oxide from a molecular hydrogel. Chem Commun (Camb). 2013;49(80):9173–5.
Cong Z, Shi Y, Wang Y, Wang Y, Niu J, Chen N, et al. A novel controlled drug delivery system based on alginate hydrogel/chitosan micelle composites. Int J Biol Macromol. 2018;107(Pt A):855–64.
Frade ML, de Annunzio SR, Calixto GMF, Victorelli FD, Chorilli M, Fontana CR. Assessment of chitosan-based hydrogel and photodynamic inactivation against Propionibacterium acnes. Molecules. 2018;23(2):E473.
Xu J, Tam M, Samaei S, Lerouge S, Barralet J, Stevenson MM, et al. Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis. Acta Biomater. 2017;48:247–57.
Karri VV, Kuppusamy G, Talluri SV, Mannemala SS, Kollipara R, Wadhwani AD, et al. Curcumin loaded chitosan nanoparticles impregnated into collagen-alginate scaffolds for diabetic wound healing. Int J Biol Macromol. 2016;93(Pt B):1519–29.
Vignesh S, Sivashanmugam A, Annapoorna M, Janarthanan R, Subramania I, Nair Shantikumar V, et al. Injectable deferoxamine nanoparticles loaded chitosan-hyaluronic acid coacervate hydrogel for therapeutic angiogenesis. Colloids Surf B Biointerfaces. 2018;161:129–38.
Chen X, Cao X, Jiang H, Che X, Xu X, Ma B, et al. SIKVAV-modified chitosan hydrogel as a skin substitutes for wound closure in mice. Molecules. 2018;23(10):E2611.
Furuike T, Komoto D, Hashimoto H, Tamura H. Preparation of chitosan hydrogel and its solubility in organic acids. Int J Biol Macromol. 2017;104(Pt B):1620–5.
Sun Y, Liu Y, Liu W, Lu C, Wang L. Chitosan microparticles ionically cross-linked with poly(γ-glutamic acid) as antimicrobial peptides and nitric oxide delivery systems. Biochem Eng J. 2015;95:78–85.
Gopal A, Kant V, Gopalakrishnan A, Tandan SK, Kumar D. Chitosan-based copper nanocomposite accelerates healing in excision wound model in rats. Eur J Pharmacol. 2014;731:8–19.
Cui FF, Pan YY, Xie HH, Wang XH, Shi HX, Xiao J, et al. Pressure combined with ischemia/reperfusion injury induces deep tissue injury via endoplasmic reticulum stress in a rat pressure ulcer model. Int J Mol Sci. 2016;17(3):284.
Makrantonaki E, Wlaschek M, Scharffetter-Kochanek K. Pathogenesis of wound healing disorders in the elderly. J Dtsch Dermatol Ges. 2017;15(3):255–75.
Arpino JM, Nong Z, Li F, Yin H, Ghonaim N, Milkovich S, et al. Four-dimensional microvascular analysis reveals that regenerative angiogenesis in ischemic muscle produces a flawed microcirculation. Circ Res. 2017;120(9):1453–65.
Al Salihi MO, Kobayashi M, Tamari K, Miyamura T, Takeuchi K. Tumor necrosis factor-alpha antagonist suppresses local inflammatory reaction and facilitates olfactory nerve recovery following injury. Auris Nasus Larynx. 2017;44(1):70–8.
Hirosaki H, Maeda Y, Shimojima M, Maeda K, Iwata H, Takeyoshi M. Effects of soluble tumor necrosis factor (TNF) on antibody-dependent cellular cytotoxicity of therapeutic anti-TNF-alpha antibody. Immunol Investig. 2019;48(5):441–50.
Jordan SC, Choi J, Kim I, Wu G, Toyoda M, Shin B, et al. Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade. Transplantation. 2017;101(1):32–44.
Yang G, Gu M, Chen W, Liu W, Xiao Y, Wang H, et al. SPHK-2 promotes the particle-induced inflammation of RAW264.7 by maintaining consistent expression of TNF-α and IL-6. Inflammation. 2018;41(4):1498–507.
Yu X, Quan J, Long W, Chen H, Wang R, Guo J, et al. LL-37 inhibits LPS-induced inflammation and stimulates the osteogenic differentiation of BMSCs via P2X7 receptor and MAPK signaling pathway. Exp Cell Res. 2018;372(2):178–87.
Sun L, Wang W, Xiao W, Yang H. The roles of cathelicidin LL-37 in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(8):1986–91.
Zhao X, Liu HQ, Li J, Liu XL. Endothelial progenitor cells promote tumor growth and progression by enhancing new vessel formation. Oncol Lett. 2016;12(2):793–9.
Jia J, Ye T, Cui P, Hua Q, Zeng H, Zhao D. AP-1 transcription factor mediates VEGF-induced endothelial cell migration and proliferation. Microvasc Res. 2016;105:103–8.
Park K, Lee HE, Lee SH, Lee D, Lee T, Lee YM. Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1,2,3-triazole compound. Oncotarget. 2017;8(5):7801–13.